A5018764701- Tryptophan and brain disorders
- Treatment of Major Depression
- Neuroscience and Neuropharmacology Research
- Stress Responses and Cortisol
- Migraine and Headache Studies
- Receptor Mechanisms and Signaling
- Digital Mental Health Interventions
- Memory and Neural Mechanisms
- Exercise and Physiological Responses
- Wnt/β-catenin signaling in development and cancer
- Neural dynamics and brain function
- Functional Brain Connectivity Studies
- Circadian rhythm and melatonin
- Mental Health Research Topics
- Axon Guidance and Neuronal Signaling
- Adipose Tissue and Metabolism
- Pluripotent Stem Cells Research
- Photoreceptor and optogenetics research
- Nerve injury and regeneration
- Transcranial Magnetic Stimulation Studies
- Mental Health Treatment and Access
- Neurogenesis and neuroplasticity mechanisms
- DNA Repair Mechanisms
- Animal Behavior and Welfare Studies
- Nuclear Receptors and Signaling
Boehringer Ingelheim (United States)
2025
Boehringer Ingelheim (United Kingdom)
2024
Yale University
2016-2023
University of Vermont
2012-2023
Click Diagnostics (United States)
2023
Pear Therapeutics (United States)
2022
Medical Research Associates
2008
Impaired function in the medial prefrontal cortex (mPFC) contributes to depression, and therapeutic response produced by novel rapid-acting antidepressants such as ketamine are mediated mPFC activity. The contains multiple types of pyramidal cells, but it is unclear whether a particular subtype mediates rapid antidepressant actions ketamine. Here we tested two major subtypes, Drd1 Drd2 dopamine receptor expressing neurons found that activating cells produces long-lasting anxiolytic...
Dysfunction of medial prefrontal cortex (mPFC) in association with imbalance inhibitory and excitatory neurotransmission has been implicated depression. However, the precise cellular mechanisms underlying this imbalance, particularly for GABAergic transmission mPFC, link rapid acting antidepressant ketamine remains poorly understood. Here we determined influence chronic unpredictable stress (CUS), an ethologically validated model depression, on synaptic markers GABA neurotransmission, a...
Stress-associated disorders, including depression and anxiety, impact nearly 20% of individuals in the United States. The social, health, economic burden imposed by stress-associated disorders requires depth research efforts to identify suitable treatment strategies. Traditional medications (e.g., selective serotonin reuptake inhibitors, monoamine oxidase inhibitors) have significant limitations, notably a time lag for therapeutic response that is compounded low rates efficacy. Excitement...
Background Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic illnesses. CT-155/BI 3972080 is prescription therapeutic under development as an adjunct to standard care patients 18 years age and older with experiential negative symptoms (ENS) schizophrenia. Individual components are designed based on the underlying principles face-to-face treatment. A...
Abstract Background and Objectives Digital therapeutics can expand the reach fidelity of behavioral treatment for substance use disorders (SUDs). This analysis evaluated real‐world engagement clinical outcomes in patients diagnosed with SUD who were prescribed reSET®, an FDA‐authorized prescription digital therapeutic (PDT). Methods Patients a 12‐week PDT comprising 61 therapy lessons (31 “core” 30 “keep learning” lessons) contingency management rewards (positive reinforcement message or...
Two weeks of voluntary exercise in group-housed mice produces a reduction anxiety-like behaviors across number different measures, including the anxiety levels typically produced by anxiogenic serotonergic drug m-chlorophenylpiperazine (mCPP), an agonist at 5-HT2C/2b receptors. We have previously demonstrated that 2-weeks blunted effects systemic mCPP, and we also shown mCPP infused into bed nucleus stria terminalis (BNST) is anxiogenic. Here follow up on these reports.In Experiment 1...
Recent reports demonstrate that the beneficial effects of voluntary exercise may be sensitive to stress prior and during wheel access period. Here, a variate procedure is used with socially isolated mice for 7 days introduction running wheels assess impact concurrent on anxiolytic effect exercise. Following exposure, functioning or nonfunctioning were introduced into stressed unstressed group-housed control cages. 3 weeks access, was assessed using acoustic startle, stress-induced...
Rapastinel, a positive NMDAR modulator, produces rapid-acting and long-lasting antidepressant-like effects; however, unlike ketamine, the abuse potential for rapastinel is minimal. Ketamine has also been shown to induce psychotomimetic/dissociative side effects, aberrant gamma oscillations, effects similar sleep deprivation, which may potentially limit its clinical use. In this study, we compared effect profile sleep-altering properties of (3, 10, 30 mg/kg) ketamine (30 in rodents. addition,...
Abstract Background Electroconvulsive seizure therapy is often used in both treatment-resistant and geriatric depression. However, preclinical studies identifying targets of chronic electroconvulsive (ECS) are predominantly focused on animal models young adulthood. Given that putative transcriptional, neurogenic, neuroplastic mechanisms implicated the behavioral effects ECS themselves exhibit age-dependent modulation, it remains unknown whether molecular cellular vary with age. Methods We...
This Retrospective observational cohort analysis of migraine patients in the US aimed to evaluate current medication costs associated with treatment Migraine, stratified by distinct groups.
Migraine affects about 14.4% of the population causing substantial burden. Our objective was to describe populations individuals diagnosed with migraine headache regards diagnosis and review healthcare service utilization across various categories. . We reviewed recent (8/2018 - 7/2021) medical pharmacy data from Health Verity for N=187,780. The final sample included 76,684 cases matched (matching criteria demographic, geographic, comorbidity, time-based variables) non-migraine controls....
To compare the populations of individuals with chronic migraine and other headache types to a matched reference (comparator) population regards migraine-specific costs care.
<sec> <title>BACKGROUND</title> Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic illnesses. CT-155/BI 3972080 is prescription therapeutic under development as an adjunct to standard care patients 18 years age and older with experiential negative symptoms (ENS) schizophrenia. Individual components are designed based on the underlying principles...